Literature DB >> 433943

Prognosis in rheumatoid arthritis. A longitudinal study of newly diagnosed younger adult patients.

S L Feigenbaum, A T Masi, S B Kaplan.   

Abstract

The course of rheumatoid arthritis was analyzed in 50 newly-diagnosed adults followed prospectively for an average of over five years. Eighteen patients had no swelling and no erosion (outcome 1), 22 patients had swelling without erosion (outcome 2) and 10 patients had erosion (outcome 3). Computer-assisted data screening and multivariate analytic technics were employed to derive a simple index from entry data which correlated closely with the patients' subsequent articular course. The index included six entry items: positive rhematoid factor; two or more swollen upper extremity joints on examination (2 points each); history of Raynaud's-like symptoms; malaise or weakness at the onset of arthritis; white race and female sex (1 point each). This index was 80 per cent accurate over-all in classifying patients into the three mutually exclusive articular outcome categories. Zero to 2 points on entry predicted no swelling, 3 to 5 points swelling without erosion and 6 to 8 points the development of bony erosion. Although results must be qualified to this patient population in the early stages of disease, the analytic approaches developed promise to assist with a broad range of clinical research and medical care delivery problems.

Entities:  

Mesh:

Year:  1979        PMID: 433943     DOI: 10.1016/0002-9343(79)91055-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  27 in total

1.  Predictors of disability in a longitudinal sample of patients with rheumatoid arthritis.

Authors:  J P Leigh; J F Fries
Journal:  Ann Rheum Dis       Date:  1992-05       Impact factor: 19.103

2.  Clinical, laboratory and genetic markers associated with erosions and remission in patients with early inflammatory arthritis: a prospective cohort study.

Authors:  A Stockman; B D Tait; R Wolfe; C A Brand; M J Rowley; M D Varney; R Buchbinder; K D Muirden
Journal:  Rheumatol Int       Date:  2005-09-07       Impact factor: 2.631

3.  Rheumatoid arthritis in Greece. Manifestations in different age groups.

Authors:  A P Andonopoulos; V Galanopoulou; A A Drosos; H M Moutsopoulos
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

4.  EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  B Combe; R Landewe; C Lukas; H D Bolosiu; F Breedveld; M Dougados; P Emery; G Ferraccioli; J M W Hazes; L Klareskog; K Machold; E Martin-Mola; H Nielsen; A Silman; J Smolen; H Yazici
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

Review 5.  Molecular mechanism of immune response, synovial proliferation and apoptosis in rheumatoid arthritis.

Authors:  T Hasunuma; T Kato; T Kobata; K Nishioka
Journal:  Springer Semin Immunopathol       Date:  1998

6.  MRI of the wrist in early rheumatoid arthritis can be used to predict functional outcome at 6 years.

Authors:  N Benton; N Stewart; J Crabbe; E Robinson; S Yeoman; F M McQueen
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

7.  Significance of rheumatoid factor isotypes in seronegative rheumatoid arthritis.

Authors:  F Eggelmeijer; H G Otten; H H de Rooy; M R Daha; F C Breedveld
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

8.  Erythrocyte complement receptor type 1 in non-SLE rheumatic diseases.

Authors:  J H Yen; H W Liu; S F Lin; T P Chen
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

9.  MRI of knee arthritis in rheumatoid arthritis and spondylarthropathies.

Authors:  A Mundinger; M Ioannidou; S Meske; E Dinkel; A Beck; G Sigmund
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

10.  Erratum: Psychoneuroimmunology: application to ocular diseases.

Authors:  Lori M Ventura
Journal:  J Ocul Biol Dis Infor       Date:  2009-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.